The high sensitivity and specificity of mpMRI and PSMA PET may obviate the need for non-targeted biopsies and reduce the over-diagnosis of prostate cancer that is not likely to be clinically significant (a Gleason score 6 or less) [65]. The gene discussed is FOLH1; the disease is prostate cancer.